DRMA
Dermata Therapeutics, Inc.
There isn't enough reported data to score DRMA yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
DRMA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
DRMA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
DRMA PE Valuation
DRMA has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
DRMA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect DRMA's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
DRMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$6.17 | +$40.19 |
| Q2 2026 | -$7.27 | +$52.99 |
| Q1 2026 | -$8.19 | +$71.90 |
| Q4 2025 | -$12.21 | +$133.97 |
| Q3 2025 | -$46.36 | -689% |
| Q2 2025 | -$60.26 | -$2.68 |
| Q1 2025 | -$80.09 | +$50.49 |
| Q4 2024 | -$146.18 | +$254.32 |
DRMA is still losing money, but far less than before: $6.17 per share over the past year, against $400.50 at its worst in late 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over DRMA on earnings quality, reporting a profit while its opponent remains loss making.
DRMA Quarterly Revenue
DRMA and OSCR do not have enough comparable growth data to identify a winner.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3856% | N/A |
OSCR has the edge over DRMA on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over DRMA on profitability, with a higher operating margin.
DRMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.7M | -$898.9K |
| Q1 2026 | -$2.5M | -$545.7K |
| Q4 2025 | -$1.3M | +$1.6M |
| Q3 2025 | -$1.8M | +$1.6M |
| Q2 2025 | -$2.7M | -$564.5K |
| Q1 2025 | -$1.9M | +$770.4K |
| Q4 2024 | -$2.9M | -$1.8M |
| Q3 2024 | -$3.4M | -$1.6M |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with DRMA at down 7.2%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
DRMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +27% | +1.1M shares |
| 1 year | +399% | +4.1M shares |
| 3 years | +23981% | +5.1M shares |
| 5 years | +157279% | +5.1M shares |
DRMA has 5M diluted shares, up 399% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over DRMA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DRMA Net Leverage
DRMA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
DRMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 11.7 | Oversold |
DRMA's weekly RSI is 26 (oversold) and its Stochastic is 12 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
DRMA PE vs Healthcare Sector
| Metric | DRMA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
DRMA has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
DRMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.89 | 26% below |
| 20 week MA | $1.12 | 41% below |
| 50 week MA | $1.40 | 53% below |
| 100 week MA | $4.63 | 86% below |
| 200 week MA | $79.3 | 99% below |
DRMA is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over DRMA on trend strength, trading above more of its moving averages.
DRMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $12,456.0 | $5,088.0 | -59% |
| 2022 | $5,088.0 | $436.6 | -91% |
| 2023 | $436.6 | $91.5 | -79% |
| 2024 | $91.5 | $13.3 | -85% |
| 2025 | $13.3 | $1.86 | -86% |
| 2026 YTD | $1.86 | $0.66 | -65% |
DRMA has finished every year since 2021 lower, and it's down 65% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over DRMA on returns for 2026, with the stronger performance.